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DESIGNING ANTI-CANCER DRUGS AND DIRECTING
ANTI-CANCER DRUG THERAPY
ELINOR VELASQUEZ, JORGE SOTO-ANDRADE, BEN BONGALON
Abstract. A prototype for a web application was designed and implemented as a guide
to be used by clinicians when designing the best drug therapy for a specific cancer patient,
given biological data derived from the patients tumor tissue biopsy. A representation of
the patients metabolic pathways is displayed as a graph in the application, with nodes
as substrates and products and edges as enzymes. The top metabolically active sub-
paths in the pathway, ranked using an algorithm based on both the patients biological
data and the graph topology, are also displayed and can be individually highlighted to
examine potential enzymatic sites to be disrupted by a drug these sites serve as a guide
for designing the patients specific drug therapy. Displayed next to each sub-path is the
sub-path score used to decide its rank, as well as the predicted patient survival time to
indicate how effective that specific drug will be in alleviating that patient’s cancer. Future
work includes an animation component to track the patients progress and re-design the
drug therapy as needed. Corresponding author’s academic email: elinor@soe.ucsc.edu.
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1. INTRODUCTION
One non-invasive method for removing a patients cancer is the use of chemotherapy or
application of cytotoxic drugs to destroy the cancer cells. The currently used cytotoxic
drugs were designed to damage the DNA in a cancer cell, but have produced mixed results
for destroying the cancer cells and restoring good health to the patient. Cancer is believed
to arise from a threshold number of gene mutations occurring in one or more cells. An
alternative viewpoint, not mutually exclusive of the gene mutation viewpoint, is that cancer
is a metabolic disease. While metabolic pathway activity is similar across healthy patients
or humans without cancer, metabolic pathway activity varies across cancer patients. Thus,
each patients cancer is unique to that patient, giving rise to a need for a personalized
medicine approach to ease cancer in that patient. Viewing cancer as a metabolic disease
permits the possibility of designing novel drugs, which disrupt metabolic pathways in cancer
cells, rapidly causing their death and quickly restoring good health to the patient.
Date: Draft 1.0 (December, 2013).
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The computer visualization website that is presented here is intended to contribute to
alleviating cancer in a patient by providing the clinician with a computational application
that 1) uses the clinical and biological data of their patient to find the best drug for
disrupting the patients cancer cellular metabolic pathways, 2) predicts a measure of efficacy
of this drug for that patient, and 3) tracks the patients progress while undergoing the drug
therapy and use the previous features of the tool to make adjustments to the drug therapy
as needed.
Current visualization tools of metabolic pathways typically have the following features in
common: Data from many patient samples are visualized instead of samples from a single
patient. Data is presented in a raw state. It is up to the clinician to decide which node or
path in the pathway to disrupt. In other words, typically nodes or paths are not ranked
in order of importance to cancer cellular activity, so the user must independently propose
the best drug for path disruption. Also, there is no metric to estimate drug efficacy if a
certain drug is applied to a specific patient. Lastly, no animation of a patients metabolic
activity yet exists to track a patients progress during drug therapy and vary the type of
drug used as needed.
2. METHODS AND MATERIALS
Here are current features of the prototype website: It accepts processed (non-raw) data re-
sulting from computations involving prior cancer, other biological studies, and the patients
data. The processed data is then displayed as edge scores to show the most metabolically
active edges in the metabolic pathways graph, as sub-path scores to show ranking of sub-
paths in the graph, and as patient survival time associated with each knocked out sub-path
or drug.
Future features of the prototype website will permit clinicians to upload a single patients
raw data and run the necessary algorithms required to compute the edge scores for the
graph, compute the scores and ranking of the sub-paths in the graph, compute the predicted
patient survival times as a result of knocking out a sub-path using a drug, track a patients
progress during drug therapy, and display score uncertainty.
The current visualization displays one metabolic pathway, the Kreb cycle, depicted as a
graph with oriented edges and nodes. A node is labeled by the key substrate or product
for a given reaction. Each edge that connects two nodes has two scores displayed, namely
the enzymes European Commission (EC) number and a score based on prior cancer and
other biological studies, and the patients tumor data, specifically, a patients microarray
mRNA expression data produced via the patients tumor tissue as well as data produced via
healthy tissue, with that healthy tissue from the patient if the patient has a primary tumor
or from tissues of healthy humans if the patient has a metastasized tumor. The current
visualization also displays a list of the top sub-paths, ranked by metabolic activity score
and displayed with predicted patient survival time post-drug therapy, tabs for uploading
data, selecting pathways, animation, and help. The visualization additionally permits
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the clinician to select a sub-path in the ranked list given on the left hand side of the
metabolic pathway and highlight that sub-path as a single colored connected set of edges
and nodes.
Hovering over an edge in the prototype visualization displays a box of annotation de-
tailing the name of the associated reaction, the Recon 2 abbreviation of the reactions
name, extracted from Thiele et al. (2013) supplementary files, the reaction formula in the
mitochondria, the enzyme EC number, the enzymes complete name, and the computed
metabolic activity score for that edge. Materials and methods
2.1. Edge weight describes metabolic activity. The edge weight in a metabolic path-
way graph extends a conception of gene activity described by Karr et al. (2012). Karr et al.
construct an equation to estimate the probability of transcribing a gene. A score for gene
transcription is derived from the rate of change of the concentration of a specified RNA
and is proportional to the gene expression value multiplied by the sum of the genes half-life
and the cell cycle time. The gene activity is obtained from dividing this gene transcription
score by the sum of all gene transcription scores. So the edge weight is a probability.
The edge weight in a metabolic pathway graph estimates the likelihood of a certain amount
of metabolic activity of an enzyme in the mitochondria during a snapshot of the reaction.
The snapshot is the biological information collected at the time of a patients cancer tis-
sue biopsy or healthy tissue biopsy. The numerator of the edge weight is defined as the
metabolic activity score and equals the reaction flux multiplied by the enzymes half-life
(obtained by mining the literature), the sum (over relevant genes) of 2x (with x the nor-
malized microarray gene expression value obtained from the biological data derived from
either the patients tumor and healthy tissue biopsies) multiplied by the genes half-life (ob-
tained by mining the literature). A model for each metabolic pathway is constructed from
the Recon 2 human metabolic pathways information (Thiele et al., 2013). Then each reac-
tions steady state flux is computed by applying the Copasi biochemical network simulator
software to the model (www.copasi.org/tiki-view articles.php), and mining the literature
to obtain values for the initial conditions and kinetic constants needed for the model. The
edge weight is the probability obtained from dividing this edge metabolic activity score
by the sum of all edge metabolic activity scores. Preferred additional data used to com-
pute the edge weight can include biological data derived from the cancer patient, involving
protein array values to estimate an enzymes translation score (that multiples the enzymes
half-life) and C13 data values for estimating the flux of the metabolic reactions.
2.2. Ranked sub-paths guide clinician when designing drug therapy for patient.
An algorithm was developed for ranking sub-paths using edge weights and the topology
of the graph. The algorithm is an adaptation of Dijkstras algorithm for computing the
most likely path configuration between two nodes A and B. The node A represents the
substrates for a metabolic reaction, the node B represents the products of that metabolic
reaction, and the edge between node A and B represents the enzyme used to catalyze the
reaction. The algorithm inputs the edge weights and outputs a list of sub-paths, ranked
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from the sub-path with highest metabolic activity to the sub-path with least metabolic
activity.
Dijkstras theorem finds the shortest path between two given nodes in a directed graph
with weighted edges. The set of all nodes is partitioned into the subset of settled nodes,
SN, whose shortest path distances from the source s are to be determined and the subset
of unsettled nodes, USN. Initially, SN is empty. While USN is not empty, the node in
USN with the minimal path distance to s is extracted, denoted n, and is added to SN. Its
nearest neighbors are relaxed: Let a given neighbor be denoted by nb. If the (direct) path
distance between s and nb, denoted d[s, nb], is greater than the (indirect) path between s
and nb via n, then d[s, nb] is updated to equal the indirect path distance which equals the
sum of d[s, n] and the weight of edge e, where e has initial node n and terminal node nb.
The predecessor of nb is then updated to be n and the while loop repeats.
See Figure 1 for an illustration of Dijkstras theorem for the triangle of nodes s, nb and n.
In this figure, the direct path distance between s and nb is 7 and the indirect path distance
equals 2 + 3 = 6. Thus, the indirect path distance is the shortest distance between node
s and node nb.
Figure 1. An illustration of Dijkstras algorithm in which the indirect path
is shorter than the direct path.
Consider now a directed graph constructed for illustrating metabolic pathways. In this
adaptation of Dijkstras algorithm, the metabolites are the nodes and the enzymes are the
edges of the graph. For a given metabolic reaction, there are one or more substrates, one
or more products and an enzyme. The substrates in a given metabolic reaction are all
represented by one node and the associated products are all represented by another node.
The enzyme for the reaction is represented by an edge between these nodes. An edge
weight equals the value of the probability distribution of metabolic activity evaluated for
a given reaction and for a given enzyme in the cell mitochondria.
The implementation of the adaptation of Dijkstras algorithm uses four data structures.
Implemented as a hash map, CurrProb is an evolving list of nodes n and their source path
probabilities, P[s, n], initialized to zero for all nodes n without a direct path to the source
node s and otherwise to a nonzero value such as the edge weight. CurrProb is updated as
DESIGNING ANTI-CANCER DRUGS AND DIRECTING ANTI-CANCER DRUG THERAPY 5
each nearest neighbor is relaxed; see below for details. The hash map Predecessor is an
evolving list of nodes and their path predecessors, and is updated as each nearest neighbor
is relaxed; see below for details. SN is the set of settled nodes in which the most likely
path has been found from the source node to the settled node. USN is the set of unsettled
nodes and equals the set of all nodes minus the set of settled nodes. Both SN and USN
are implemented as priority queues and are reverse ordered according to each nodes source
path probability, P[s, n], with s the source node and n the node; the maximum probability
is at the top of the queue.
The input to the algorithm is a node pair (A, B). The most likely sub-path between A and
B and its sub-path score, P[A, B], are output by the algorithm. The output is described
by a sequence of intermediate node pairs (a, b) (the Predecessor hashmap) and P[A, B]
= (1/N) P[a, b], with N the number of node pairs (a, b). An intermediate node pair
equals the initial node a and the terminal node b. P[a, b] equals the maximum edge weight
over all the edges that connect node a to node b and have Hamming distance d(a, b) =
1. A wrapper is used to iterate the algorithm over all nodes A and B in the graph and
the wrapper output is a list of the top sub-paths in the graph, ranked by the sub-path
scores.
The algorithm proceeds as follows. CurrProb is initialized as previously described. The
source node, A, is fixed and the target node, B, is fixed. A is added to the priority queue
SN and the probability of each neighbor n of A, P[A, n], is computed and the neighbor with
the maximum P[A, n] is added to the priority queue USN. While USN is not empty, extract
the top queued node from USN; call it ntop. Add ntop to the priority queue SN, then relax
the neighbors of ntop: If neighbor nb belongs to SN, ignore this neighbor. Otherwise,
check if the probability P[A, nb] is less than P[A, ntop] times P[ntop,nb]. If so, set P[A,
nb] equal to P[A, ntop] times P[ntop, nb] and update both the CurrProb hash map and
the USN priority queue (which is reverse ordered according to P[A, nUSN], for all nodes
nUSN in the USN). The predecessor of nb is set to be ntop and the Predecessor hash map
is updated. After the while loop exits, the path configuration is described by the elements
in Predecessor. Lastly, the node A, the node B, the elements of Predecessor, and P[A, B]
are presented as output.
2.3. Metric predicts efficacy of drug therapy pre-treatment. A metric was devel-
oped to estimate the efficacy of a proposed drug therapy for a cancer patient. Current
implementation of the visualization permits the clinician to inspect the ranked list of sub-
paths and select one or more sub-paths to knock out. Note that the algorithm ranking
sub-paths assumes that at least one reaction is involved in a sub-path. For the initial
description of the metric, suppose a sub-path has only one reaction: A reaction usually
has both upstream and downstream reactions to it. If a reaction is knocked out, the down-
stream reactions will all be knocked out as well as some of the upstream reactions if the
primary reaction is reversible. The current implementation of the metric considers only
downstream reactions.
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The efficacy of a proposed drug is estimated by predicting survival time (lifespan) of a
cancer patient if the drug is used in the patients anti-cancer drug therapy. The metric is
defined as a simple linear regression, Y = mX + b, with Y the patients predicted survival
time (post-drug therapy), X the edge weight for a given edge in the metabolic pathways
graph, b the Y-intercept, and m the slope. The values m and b are the solution obtained
by minimizing Q(m,b), with Q(m,b) = (Yi b mXi)2, with the sum over all pairs (Yi,
Xi):
The pairs (Yi, Xi) are taken from prior cancer studies that contain the following data
types: survival times of cancer patient who have undergone a specific enzyme-inhibitor
drug therapy, and microarray gene expression values derived from patients cancer tissue
biopsies and additionally healthy tissue biopsies from either the patient or non-patients
(in the case of metastasized cancer). Preferred additional data used to compute the edge
weight can include biological data derived from the cancer patient, involving protein array
values to estimate an enzymes translation score (that multiples the enzymes half-life) and
C13 data values for estimating the flux of the metabolic reactions.
The sum in the simple linear regression is taken over all the reactions that the enzyme
catalyzes, and all reactions downstream of these disrupted reactions.
3. IMPLEMENTATION
The visualization component uses the GraphViz tool, http://graphviz.org/, to generate
metabolic graphs. Using GraphViz brings two key benefits. First the metabolic pathways
can be described at a high level, and the tool automatically takes care of laying out the
graph. Secondly, GraphViz can generate the graphs in SVG (Scalable Vector Graphics)
format. This allows the graph to be arbitrarily resized without pixelation.
After the SVG graph is created, the D3.js tool, http://d3js.org/, is used to add anno-
tations, highlight pathways and manipulate the image. D3.js is a JavaScript library for
manipulating documents based on data, including SVG. The entire application is hosted
on Google App Engine, https://developers.google.com/appengine/.
Figure 2 displays the current implementation of the visualization.
4. CASE STUDIES
The metabolic pathway that is currently displayed in the visualization is the citric acid
cycle (TCA or Kreb cycle) in a cells mitochondria, used to completely oxidize glucose,
producing energy that is carried by NAD and FADH to the electron transport chain so ATP
can be outputted. Mutations in genes associated with the TCA cycle enzyme, isocitrate
dehydrogenase, have already been linked to tumorogenesis [Parsens, et al., 2008], [Yan, et
al., 2009]. Also, the TCA cycle enzyme, fumarate hydratase, is mutated in some tumors.
DESIGNING ANTI-CANCER DRUGS AND DIRECTING ANTI-CANCER DRUG THERAPY 7
Figure 2. OncoMira: Pathway visualizer for cancer cells application dis-
playing the beginning of the Kreb cycle. The top three ranked sub-paths,
their path scores (the listed numbers are temporary placeholders), and the
patients predicted survival time (the listed numbers are temporary place-
holders) if a drug knocks out that sub-path are displayed on the left hand
side of the screen. The blue bold number on most edges represents the
edge weight. The lack of a blue bold number means that the edge does not
have either patient derived or literature derived data to complete the cal-
culation for the edge weight; the missing information has to be estimated.
This information and the resulting uncertainty in the edge weight because
of this lack of information will be displayed in future implementations. The
black number represents the European Commission enzyme identification
number for an edge. Selecting a specific sub-path colors the relevant nodes
and edges on the graph.
Romero et al. predicted approximately over 130 predicted metabolic pathways in humans
[Romero, et al., 2004].
The reaction flux (with initial conditions from Wu et al. (2007)) multiplied by the enzymes
half-life (data obtained from experiments by Patrick et al. (2012), the sum (over relevant
genes) of 2x (with x the normalized microarray gene expression value obtained from The
Cancer Genome Atlas glioblastoma multiforme Agilent dataset) multiplied by the genes
half-life (data obtained from experiments by Friedel et al. (2009)). The edge weight is the
probability obtained from dividing this edge metabolic activity score by the sum of all edge
metabolic activity scores. Preferred additional data used to compute the edge weight can
include biological data derived from the cancer patient, involving protein array values to
8 ELINOR VELASQUEZ, JORGE SOTO-ANDRADE, BEN BONGALON
estimate an enzymes translation score (that multiples the enzymes half-life) and C13 data
values for estimating the flux of the metabolic reactions.
5. CONCLUSIONS AND FUTURE WORK
Future implementations of the visualization will annotate the clinicians selected list of
sub-paths with a candidate list of drugs, composed of one or more drugs known to disrupt
the sub-path or novel drugs. The list for each sub-path will contain at least novel drugs,
because there does not yet exist a drug available to knock out every reaction in the hu-
man metabolic pathways. These novel drugs are enzyme-inhibitor drugs specific to each
metabolic reaction and will be computationally designed (and ideally pre-tested on cancer
tissue cultures or in clinical trials), using already developed computational tools: There
is currently available open-source virtual screening software to discover candidates of en-
zyme inhibitors. Auto Dock, http://autodock.scripps.edu, is the open source standard for
molecular docking investigations. Open source PyRx, http://pyrx.source forge.net, uses
AutoDock to accomplish high-throughput virtual screening. PyRx will be used with the
selected enzyme or enzymes as input and output candidates for small molecule enzyme
inhibitors.
Future implementations of the visualization will include animation to track a patients
progress during drug therapy. The goal of the animation is to see the rate of change between
the previous time step (time t0 of no drug application or time ti of a drug application) and
the latest drug application (ti+1) in order to decide if the drug is significantly affecting
the desired sub-paths and whether new sub-paths are among the top-ranked sub-paths,
causing a new drug to be used in the drug therapy. Additionally, uncertainty in the data
will be reflected in future implementations of the visualization.
Future work includes evaluating metric accuracy: Future work will evaluate metric that
predicts drug efficacy pre-drug therapy. Possible techniques include using experimental
data to estimate accuracy of metric, simulating data and providing error bounds, finding a
gold standard to evaluate the metric. Experimental data requirements are that the overall
survival time for each cancer patient must be recorded, the type of enzyme-inhibitor drug
used in the clinical trial or study must be known, and the gene expression data for each
patient in study must be provided.
To conclude, a web tool was created to guide the clinician in providing a cancer patient
with a personalized drug therapy, directly using the patients biological data, as well as
biological and cancer data from a variety of prior studies. The philosophy behind the web
tool relies on the view that cancer is a metabolic disease and disrupting key metabolic
sites in the cancer tissues can best restore a patients health. The current implementation
features a graph representing an important metabolic pathway, along with a ranking of
top metabolically active sub-paths in this pathway, and provides scores used to rank these
sub-paths, along with an additional score that predicts the efficacy of a drug targeting
metabolic sites in that patient pre-drug therapy application.
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